Asbestos lung mesothelioma – The risk of lung cancer spread to the brain

August 31st, 2010

brain metastasis refers to when a cancer in the body extended to the brain from another location in the majority rule, lung or breast. May be one or more brain metastases, and cancer can go to different areas of the brain.

The primary lung cancers account for 50% of all metastatic brain tumors. Lung cancer is the most common source of metastases. Among patients with lung cancer who survive for more than 2 years, 80%Brain metastases received.

http://www.asbestoslungmesotheliomaaa.goodarticlesite.com/the-risk-of-lung-cancer-spread-to-the-brain/

The average time between diagnosis of primary lung cancer and brain metastases is four months. Charming, small cell carcinoma, the lungs are only 20% of all cancers, accounting for 50% of metastatic brain cancer. In a retrospective study to 6.8% of first recurrence of cancer was in the brain.

http://www.asbestoslungmesotheliomaaa.goodarticlesite.com/the-risk-of-lung-cancer-spread-to-the-brain/

Metastatic disease from breast, kidney cells of the thyroid, colon and are usually more than a single metastatic lesion,while metastatic disease from lung cancer and melanoma are found to be generally very, multiple lesions. Testicular cancer is a rare tumor and yet it is increasingly common in brain metastases compared with lung cancer.

Lung cancer can also pass through the bloodstream to other parts of the body, most typically in the liver, adrenal glands, brain, spinal cord or bones. The spread of lung cancer may occur early in the disease course, with all previoussmall cell lung cancer. symptoms, including headaches, seizures, confusion, bone pain, and can obviously grow a lung problems first, making early diagnosis difficult.

READ MORE http://www.asbestoslungmesotheliomaaa.goodarticlesite.com/the-risk-of-lung-cancer-spread-to-the-brain/

Asbestos lung mesothelioma – A family history of lung cancer

August 31st, 2010

The lungs are the body responsible for breathing. Lung cancer is caused by cellular alterations of malignant tumor development in one. The factors that lead to disease are different.

http://www.asbestoslungmesotheliomaaa.goodarticlesite.com/a-family-history-of-lung-cancer/

Researchers are examining the effects of family history of cancer. It ‘possible that there is at least one defective gene that lung cancer would be passed down in families. If you have a first degree relative with cancer, the risk is doubled. It ‘very difficult to sort thatThe facts here as a result of the role of smoking. Smokers all families will be exposed to cigarette smoke, and then have a higher risk if they have inherited a faulty gene or not.

But while tobacco is the most important risk factor, family history plays an important but secondary role. People with a family history of lung cancer might be less of an ability to repair DNA damage of smoking, resulting in increased incidence of unpleasantCancer.

There is increasing evidence that genetic factors [for your] family history may be at risk as part of the cause of lung cancer. The chemical carcinogens in cells, lung cells for biochemical processes including the fact yours. Genes determine these processes. A number of genes could allow more of the carcinogenic chemicals are produced that allow other genes, perhaps less

READ MORE http://www.asbestoslungmesotheliomaaa.goodarticlesite.com/a-family-history-of-lung-cancer/

Cough is an important symptom of lung cancer

The symptoms of lung cancer are in his way, his position and how it spreads. One of the most common symptom is a persistent cough or people who have a chronic cough, a change in the character of the cough. A row of people coughing blood or sputum streaked with blood.

Cough is a symptom of lung cancer significantly, but it is difficult to distinguish, cough cough associated with lung cancer and cough associated with smoking orchronic lung diseases like COPD, smoking caused associated. If a patient who had a chronic cough shows changes in the pattern of a cough, a possibility of cancer must be considered.

A cough from lung cancer, shortness of breath and coughing up blood are the symptoms, in essence, to you in two forms, small cell carcinoma and non-small cell lung cancer.

READ MORE http://www.asbestoslungmesotheliomaaa.goodarticlesite.com/cough-is-an-important-symptom-of-lung-cancer/

Smoking, The Main Cause of Lung Cancer

August 31st, 2010

As you have probably known that the number of people with lung cancer is increasing dramatically. This mainly caused by the people’s unawareness on the source of lung cancer. There are many factors that can cause lung cancer. The heavy air pollution can be the source of the lung cancer but the biggest source of lung cancer is the smoking habits. This can be true because the research shows that 90% of people with lung cancer are smokers. Smoking is an activity inhaling smoke from cigarette. When tobacco is burning as a cigarette and people inhale it, there are many dangerous materials are also inhaled. Tobacco has several dangerous materials such as tar and Nicotine. When the tar and nicotine are inhaled, it covers the lung surface with a layer. When you continue smoking for many years, the layer is getting thicker and it blocks the process of oxygen absorption. As you may know that lung is the only oxygen supplier for the whole body. The blood stream takes the oxygen from the lung and brings it to all parts of the body. When the surface of the lung is layered with tar and nicotine, the lungs are not able to absorb oxygen well. And when it can’t absorb oxygen, the body will not get enough oxygen supply. As the result, your body will not do their job as it was. Moreover, when the lungs are covered by the tar and nicotine, it can cause the lung cell to grow uncontrollable. The lung cell will grow wild and it cause lung cancer. When the cells grow wildly, it forms a swelling. The swelling is of course very hurt and it can be very big too. The research shows that the lung cancer can block your breath system and you will die.

Unfortunately, cancer can spread away. If the blood stream makes a contact with the cancer cells, it brings the cancer seed to the whole body. in other word, the cancer is spreading. This is the most dangerous situation because you don’t where another cancer will grow. When you have lung cancer, it is better for you to stop smoking. Stop smoking is really hard but it may avoid you from the death. If the lung cancer is visible you will need to see doctor and take some medicines. You will also need to undergo some treatments to make the cancer disappear.

Women who are smoking have risk of dying 12 times greater of lung cancer. Moreover, smoking can cause many other illnesses such as bronchitis and cough. If you want to know more about the relation between smoking and lung cancer, you can read many articles about it on the internet. You can just open your computer and get informed how dangerous the lung cancer is.

My other article about mesothelioma are asbestos lawyer mesothelioma and asbestos mesothelioma lawsuit.

Toxic Carcinogens Silence Genes Causing Lung Cancer

August 30th, 2010

Individuals may find an increased risk of lung cancer due to the silencing or chemical modification, also known as hypermethylation, of a gene, according to a recent issue of the American Association for Cancer Research.

The Science Daily news article reported that after smoking, a patient may develop “tobacco-mediated hypermethylation”.

Through the development of these findings, it becomes much easier for scientists to treat lung cancer by reversing the process of “silencing” the gene, which has been identified as MTHFR, which upon modification induces a stronger surge of lung cancer development.

The study also noted that through the consumption of such dangerous carcinogens, such as tobacco smoke and potentially asbestos fibers, there may be the development of genome damage, which can cause mutations among genes, and eventually silencing them through chemical modification, which in turn also will cause the increase of lung cancer progression, according to scientists.

Mesothelioma Lung Cancer

Mesothelioma cancer is what the National Library of Medicine has deemed a “cancer of the tissue” and it effects the mesothelium “tissue that lines the lungs, stomach, heart and other organs.” The National Cancer Institute (NCI) reported the following mesothelioma signs and symptoms including:

* shortness of breath

* pain in the chest

* accumulation of fluid in the chest

* weight loss

* abdominal pain

* sweling in abdomen

* bowel obstruction

* blood clotting

* fever

* anemia

Litigation Involving Mesothelioma Cases

Individuals who have suffered from a mesothelioma diagnosis are encouraged to utilize a free legal consultation from an experienced mesothelioma attorney. It may be a necessary step to develop a mesothelioma lawsuit.

Becoming involved in a mesothelioma lawsuit may provide compensation for a mesothelioma victim.

Additionally, creating a mesothelioma lawsuit and obtaining money as an award for damages endured may assist a victim in paying for costly treatments. Chemotherapy, which is one of the main treatments for mesothelioma side effects, often costs thousands of dollars.

For more information on a mesothelioma lawsuit, individuals can visit the LegalView information portal to obtain updated information.

Mesothelioma is often considered a fatal condition, which is why it is imperative that an individual know the details behind the condition.

LegalView (http://www.LegalView.info ) offers an array of legal information through its legal library. Topics range from mesothelioma news (http://mesothelioma.legalview.info ) to obtaining a truck accident attorney as well as how to find Nephrogenic Systemic Fibrosis treatments.

Why Only Some Smokers Get Lung Cancer?

August 30th, 2010

Smoking is the most potent known cause of lung cancer. The question is: Why do some longtime smokers come down with the deadly disease whereas others escape it? New research points to a genetic culprit that also was fingered as upping a person’s likelihood of becoming hooked on cigarettes.

Two new studies link a variation in a gene residing on chromosome 15 (of a person’s 23 pairs of chromosomes) to a heightened risk of developing lung cancer; a third study suggests that the same mutation affects a person’s tendency to become addicted to smokes and, by extension, develop the dreaded disease. Lung cancer is diagnosed in some 200,000 Americans and kills more than 150,000 each year.

The new research—published in both Nature and Nature Genetics—suggests that people with this genetic flaw have a 30 percent greater chance of developing the often-fatal illness. But the studies differ on the potential added risk of addiction. The findings offer insight into how this particular genetic variation and smoking interact to cause lung cancer. They provide “new targets for starting to think about how to treat drug addiction and, also, of course, for the prevention or treatment of lung cancer,” says Nora Volkow, director of the National Institute on Drug Abuse (NIDA) in Bethesda, Md., who was not involved in the study.

The research teams scanned a catalog of 300,000 minute changes in the genome in which a base (unit of genetic material) was either deleted, duplicated or substituted. (Such alterations are known as single nucleotide polymorphisms, or SNPs.) In one study, scientists from Iceland-based biotechnology company deCODE genetics tried to correlate these genetic variants with a person’s smoking habits; the other research efforts attempted to tie them to lung cancer.

The deCODE group surveyed 50,000 Icelandic smokers about their habits; using information gleaned from that survey as well as from genomic scans of 40,000 admitted smokers in the bunch, the researchers zeroed in on a variant of the gene CHRNA, which codes for a receptor on nerve cells that can be stimulated by nicotine. The altered version of the gene was more common in the heaviest smokers than it was in the rest of the population. “Nonsmokers have a higher frequency of this variant than smokers that smoke between one to 10 cigs per day,” notes neurologist Kári Stefánsson, deCODE’s CEO, “because if you smoke and you have this variant, you tend to smoke more than 10 cigs per day.”

When Stefánsson’s team applied the stats to the incidence of lung cancer, it found that individuals with two copies of the altered gene had a whopping 70 percent greater chance of developing lung cancer; those with one copy had a 30 percent higher risk.

These findings are virtually identical to those of the other studies—one (in Nature) conducted by the International Agency for Research on Cancer (IARC) in Lyon, France (which was based on examinations of some 11,000 volunteers, 7,500 of whom were smokers) and the other (in Nature Genetics) by a team at the University of Texas M.D. Anderson Cancer Center in Houston, which examined 9,000 individuals, some 4,000 of whom were smokers.

Paul Brennan, who led the IARC study, says he initially believed that the risk of getting lung cancer was elevated by the genetic predisposition to become addicted. “The genes made you more likely to smoke, made you likely to smoke more, made you less likely to give up, and therefore more likely to develop lung cancer,” he says. But his research showed that, in fact, the gene appeared to independently increase a person’s risk of developing the disease—with no link to addiction.

NIDA’s Volkow suggests that the gene variant may lead certain individuals to smoke more due to its effect on the brain’s reward centers (associated with addictive behavior) and may increase the risk of cancer, too, because it also plays a role in lung tissue function. Epidemiologist Christopher Amos, who led the Texas study, notes that the same nicotine receptor implicated in this study was shown in previous research to prompt tumor growth in other areas of the body, most notably the thymus (an organ located near the lungs that produces immune cells). “Nicotine or its derivatives can stimulate cells to proliferate, participate in new blood vessel development, and also not undergo cell death,” he says, which are all characteristics of tumor formation and growth. “So that raises the possibility that there’s a direct effect through nicotine in activating cells to go on to become cancerous.”

Brennan says more research is needed before the findings can be put into play.

“There’s not a public health message here that you can find out what version of the gene you have and decide whether to keep on smoking or not,” he says. “You have to bear in mind that there are so many other disease[s] that are caused by smoking.”

Jigfo.com is a global platform for sharing and learning knowledge and is simple and easy way to access information on thousands of topics. Jigfo.com has brought information to our finger tips. It is easy to access and gives detailed information on any topic. It has question and discussion section for each topic making sharing knowledge a simple task. For more information on this article topics visit:

http://cancer.jigfo.com/

http://breastcancer.jigfo.com/

http://britishjournalofcancer.jigfo.com/

http://cancerimmunotherapy.jigfo.com/

http://clinicalimmunology.jigfo.com/


Try Jigfo today, or even start your contribution to the world wide web by making an information page on Jigfo today!

http://www.jigfo.com

Lung Cancer – Facts, Prevention And Treatment

August 30th, 2010

Many smokers tend to quit at least once if not twice in their lifetime. Yet, they may not utilize several techniques to help them completely quit thus getting stuck in a cycle of not being able to stop. However, if a smoker wants to prevent being diagnosed with lung cancer, it’s vital they get some help. What kind of help is there?

- Nicotine gum
- Nicotine inhalers
- Nicotine sprays; among many more

Smokers already know how to lessen their chances of getting lung cancer. Yet, non smokers are still at risk of getting lung cancer by being exposed to passive smoking. Non smokers may be exposed to radon gas and not even know it. For that reason, radon gas test kits are important in identifying the levels of gas inside their home. Radon gas is capable of causing lung cancer to appear in non smokers with limited history of passive smoking.

Doctors can use the helical low-dose CT scan to help them to identify and diagnose lung cancer in patients. These scans may be able to detect smaller cancers that are usually cured by surgical means thus preventing the spread of an incurable cancer.

The Facts behind Lung Cancer

Of all cancers, including breast cancer in women, diagnosed in the United States and around the globe, this disease is the primary killer in men and in women.

Despite the existence of passive smoking, cigarette smoking, not including cigar smoking, is a main favor behind lung cancer growth.

When a non smoker is exposed to tobacco smoke, there is an increased risk lung cancer due to the passive smoke.

There are actually two forms of lung cancer. The first is small cell lung cancers or SCLC. SCLC has been found to be the most aggressive. Survival of this aggressive cancer when it is untreated is about two to four months. Yet, it does respond well to chemo and radiation therapies. Survival rate increases through this treatment methods. The second is non small cell lung cancer or NSCLC. Cancers of this form usually will need to be surgically removed to be an effective treatment method. A small number of patients with SCLS can be helped by radition therapy. However, if the disease is in its advanced stages, there is a small chance of survival through chemotherapy treatment.

How extensive the disease, the size of the tumor, what sort of symptoms the patient has and the kind of lung cancer will determine at what stage the lung cancer is classified by doctors. Physicians will use x-rays, MRI scans, CT scan and bone scans to also determine the stage of the lung cancer.

Lung cancer treatments can involve any number of options including chemotherapy, radiation therapy and surgery. Treatments may also be combined to achieve success in beat the cancer. Some lung cancer patients may be invited to participate in experimental treatments.

Lung cancer survival, unlike other cancer types, has a low rate. Generally, survival rates are approximately 16 percent for five years.

Quitting smoking is the most vital way that can reduce the chances of getting lung cancer.

eCancerAnswers.net is a comprehensive Cancer guide that covers topics from Cancer to Cancer Risk Factors and Breast Cancer.

Causes of Lung Cancer – Information You Need to Know

August 30th, 2010

More men and women die from lung cancer than any other cancers. Who is most susceptible to this disease? Nearly 70 percent of the elderly 65 and older will be diagnosed with this disease. Three percent of lung cancer cases have appeared in people younger than 45 years old.

Until the 1930s, cancer of the lungs was not as prevalent but still quite common. However, once there was an increase of tobacco smoking use, lung cancer cases rose drastically. As information and education circulates about the hidden dangers of smoking, lung cancer related deaths are beginning to see a decline. Despite all the education and the public awareness, it’s still a common human cancer. For women, breast cancer is no longer the number one killer. Lung cancer has exceeded breast cancer related deaths.

Lung Cancer Causes

Smoking – Most lung cancer related deaths (about 90 percent) have been associated with smoking. Each time a person smokes a cigarette, they increase their chances of getting lung cancer. Based upon doctors’ formula regarding the quantity of packs to the amount of years smoked, someone who has a 30 pack to year history has a greater chance to develop lung cancer. For those people who smoke two, three or more packs a day, statistics show that one in seven diagnosed will die from the disease. Cigarette smoking is not the only culprit to lung cancer. Cigar smoking and pipe smoking can also lead to the disease at a lower rate. Those who smoke cigars or pipe smoke are five times more likely to get lung cancer than a person who never smoked.

The smoke found in tobacco has over 4,000 element compounds. Many of these are cancer causing. Two key carcinogens are polycyclic aromatic hdrycarbons and nitrosamines. Once a person has given up tobacco use, lung cancer risks decreases every year. Normal cells will begin to grow and outnumber damaged lung cells. After 15 years of not smoking, lung processes and the threat of the disease gets close to that of someone who has never smoked.

Passive Smoking – What is passive smoking? This is when people who are in close quarters smokers breathe in the smoke filled air. Those who don’t smoke have a 24 percent likelihood to develop lung cancer if they live with a smoker. Nearly 3,000 deaths can be associated with passive smoking.

Asbestos Fibers – Mesothelioma and lung cancer through asbestos exposure is high. People who work in asbestos related fields and smoke dramatically increase their chances of getting a lung cancer connected disease. When compared with their non smoking counterparts, they have a 50 to 90 percent greater risk of getting lung cancer or other lung related illness.

Radon Gas – Radon gas has been documented to be the next leading cause in lung cancer deaths, killing anywhere from 15,000 to 22,000 people in the United States every year. Like asbestos exposure, radon exposure augments lung cancer risks. The gas is able to travel through soil. It can gain entrance into homes by the gaps found in its foundation, its drains and its pipes. Nearly one in 15 homes is found with dangerous level of radon gas according to the United States Environmental Protection Agency. Can a person tell if their home has high amounts of radon gas? Only by a kit. The gas cannot be smelled, nor can be it seen.

Genetics – It’s true that most cases of lung cancer can be linked back to smoking. However, not every smoker will get the disease. That means other factors like genetics could play a part behind the causes of lung cancer. Studies have revealed that cancer can and does occur in families that have smokers and nonsmokers. It would seem a gene can increase the vulnerability of smokers in getting lung cancer.

Lung Diseases – When a smoker or even non smoker has other lung diseases such as COPD (chronic obstructive pulmonary disease), they are at an increased risk to develop the disease even if they quit smoking and all the effects have worn away.

History of Lung Disease – People with a record of lung cancer are at a higher risk of developing it a second time. People who have survived a non-small cell lung cancers have a one to two percent risk to getting the disease a second time while those who have beaten small cell lung cancers have a six percent increase each year.

Air Pollution – The chances of getting lung cancer from air pollution is raised in individuals that breathe in polluted air every day. Pollution from cars, power plants and industrialized areas increases these risks. Yet, they only account for one percent of lung cancer related deaths. Experts have suggested that every day exposure to air heavily polluted can be compared to passive smoking.

eCancerAnswers.net is a comprehensive Cancer guide that covers topics from Cancer Symptoms to Breast Cancer and Cancer Treatment.

Non-Small-Cell Lung Cancer (NSCLC) – Drug Pipeline Analysis and Market Forecasts to 2015 -Aarkstore Enterprise

August 30th, 2010

The industry analysis specialist’s new report, “Non-Small Cell Lung Cancer (NSCLC) – Drug Pipeline Analysis and Market Forecasts to 2015″ is an essential source of information and analysis on the global NSCLC disease market. The report identifies the key trends shaping and driving the global NSCLC disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global NSCLC disease sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by  team of industry experts.
 estimates the global NSCLC disease market to be $2.8 billion in 2008. It is forecast to grow at a compound annual growth rate (CAGR) of 13.5% for the next seven years to reach $6.8 billion by 2015. This growth is primarily attributed to increased disease population and strong pipeline with more emerging therapies. The available treatment options are moderately successful in meeting the market demand. There exists a significant market potential to be tapped for any new entrant that will cater to the unmet needs. There is enormous opportunity for any drug that would offer better efficacy provided by the current players with increased safety than the current products.

finds that that the emerging therapies in pipeline are expected to increase the competition. Emerging therapies have gained a positive perception among the physicians due to increased efficacy, safety and overall survival. The strong pipeline leads to the stiff competition in the NSCLC market and the existing market leaders need to be prepared to manage this expected dynamism in competition as there is a race to reach the blockbuster drug status.

Scope

The report analyzes market opportunities and challenges for the global NSCLC disease market. Its scope includes
- Annualized global NSCLC disease market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
- Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes tyrosine kinase inhibitors, microtubules, protein kinase inhibitors, cell division inhibitors, ERBB3 antagonist, DNA and RNA synthesis inhibitors, C-Met or ALK Inhibitors, glutathione S-transferase binders, growth and survival of MM cells inhibitors, HER2 dimerization inhibitors, antiangiogenesis inhibitors, cyclooxygenase-2 (COX-2) inhibitors, Pan Bcl-2 inhibitors and MUC1 tumor-associated antigens etc.
- Analysis of the current and future market competition in the global NSCLC disease market. Key market players covered are F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG, Sanofi-aventis, Boehringer Ingelheim GmbH, and Abraxis BioScience, Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with NSCLC disease.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global NSCLC disease market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global NSCLC disease market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global NSCLC disease market landscape? – Identify, understand and capitalize.” $2,000 $4,000 $6,000 GDHCPRT020 Pharmaceuticals and Healthcare Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action, tyrosine kinase inhibitors, microtubules, protein kinase inhibitors, cell division inhibitors, ERBB3 antagonist, DNA and RNA synthesis inhibitors, C-Met or ALK Inhibitors, glutathione S-transferase binders, growth and survival of MM cells inhibitors, HER2 dimerization inhibitors, antiangiogenesis inhibitors, cyclooxygenase-2 (COX-2) inhibitors, Pan Bcl-2 inhibitors, MUC1 tumor-associated antigens 
 

For more information,please visit:

http://www.aarkstore.com/reports/Non-Small-Cell-Lung-Cancer-NSCLC-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015-40590.html

Minal H
SEO
vinod.minal@gmail.com
http://www.aarkstore.com

Non-Small-Cell Lung Cancer (NSCLC) – Drug Pipeline Analysis and forecast

August 30th, 2010

Non-Small-Cell Lung Cancer (NSCLC) – Drug Pipeline Analysis and Market Forecasts to 2015

This is an essential source of information and analysis on the global NSCLC market. The report identifies the key trends shaping and driving the global NSCLC market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global NSCLC sector. ( http://www.bharatbook.com/detail.asp?id=128441&rt=Non-Small-Cell-Lung-Cancer-NSCLC-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015.html )

Scope

The scope of the report includes:
- Annualized global NSCLC market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
- Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes tyrosine kinase inhibitors, microtubules, protein kinase inhibitors, cell division inhibitors, ERBB3 antagonist, DNA and RNA synthesis inhibitors, C-Met or ALK Inhibitors, glutathione S-transferase binders, growth and survival of MM cells inhibitors, HER2 dimerization inhibitors, antiangiogenesis inhibitors, cyclooxygenase-2 (COX-2) inhibitors, Pan Bcl-2 inhibitors and MUC1 tumor-associated antigens etc.
- Analysis of the current and future market competition in the global NSCLC market. Key market players covered are F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG, Sanofi-aventis, Boehringer Ingelheim GmbH, and Abraxis BioScience, Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with NSCLC.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global NSCLC disease market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global NSCLC disease market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global NSCLC disease market landscape? – Identify, understand and capitalize.
 

To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=128441&rt=Non-Small-Cell-Lung-Cancer-NSCLC-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook

We are the leading information aggregator, facilitates and supports the business information needs. With over 115,000 reports, you can get instant access and insights on the studies in yo for market research , corporate / strategic planning by providing the latest information in the form of reports, journals, magazines and databases on varied industries like automotive, oil and gas, shipping, textiles, pharmaceuticals, energy, banking, finance, insurance, risk management, country intelligence, consumer & durable goods, chemical and more ur areas of interest. Contact us at +91 22 27578668 / 27579438 or email info@bharatbook.com or our website www.bharatbook.com

Football Legend Succumbs To Mesothelioma Lung Cancer

August 30th, 2010

Hall of Fame football player, broadcaster and actor Merlin Olsen has died at age 69 of mesothelioma, a rare but deadly form of lung cancer.

Olsen was a member of the “Fearsome Foursome” of the Los Angeles Rams, and was selected to 14 consecutive Pro Bowls, a tie with Bruce Matthews for the longest streak in league history. In 1992, Olsen was inducted into the Hall of Fame.

As his football career ended, Olsen became an actor, with appearances on shows like “Little House on the Prairie” and “Father Murphy” as well as acting as a spokesman for FTD Group Inc.’s flower commercials. Furthermore, he was an avid college football commentator – Olsen was the voice of college football’s Rose Bowl from 1980 until 1988.

Olsen began chemotherapy after his initial diagnosis in 2009. Mesothelioma is a type of lung cancer caused by exposure to asbestos that attacks the lining of the lungs, heart or abdomen. Although rare, mesothelioma patients often have a grim prognosis.

Mesothelioma can take upwards of 30 to 40 years to manifest, which makes it difficult to ascertain when the initial exposure occur. The World Health Organization has identified asbestos as a dangerous carcinogen, in which there are no safe levels of exposure. Ban Asbestos and other organizations are currently seeking a worldwide ban of the asbestos in all capacities, however it is a popular construction material in developing countries. In the United States, it can still be found in products in quantities of less than 1 percent.

Olsen claims he was exposed to asbestos as young as 10 or 11 years old in a mesothelioma lawsuit he filed in 2010. He also stated he may have been exposed while working in the construction industry while in high school and college. Many lawsuits have been filed against companies that did not warn individuals of the risks of exposure as far back as 50 years ago, including Olsen’s lawsuit.

Due to the hazardous nature of the fibrous substance, a licensed contractor is required by law in the United States to remove asbestos. The often time-consuming process is necessary to prevent civilians from exposure. Because asbestos was a common construction fiber, many older buildings may be contaminated, unbeknownst to its occupants.

Olsen’s fame has brought the threat of mesothelioma into the media spotlight, as many individuals may be unknowingly exposed. Contact your local health department if you suspect asbestos contamination, but do not try to remove material.

Get a FREE consultation with an experienced mesothelioma attorney at http://mesothelioma.legalview.com/ and learn more about the lung cancer caused by asbestos exposure. In addition to environmental toxin litigation, LegalView.info has a wealth of information related to traumatic brain injuries and personal injury litigation.